Added to YB: 2025-11-11
Pitch date: 2025-11-06
MDNA.TO [neutral]
Medicenna Therapeutics Corp.
-25.68%
current return
Author Info
Penny Queen focuses on undiscovered value, deep dives, swing trades and special situations. Sign up for the newsletter.
Company Info
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases.
Market Cap
CAD 133.5M
Pitch Price
CAD 1.48
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.42
P/E
-9.33
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Quick Hits: 8 Portfolio Updates from Hydrogen to Healthcare - Medicenna (MDNA.TO)
MDNA.TO (update): IL-2 space validated by $11.5B competitor deal. Smart neoadjuvant melanoma trial NEO-CYT tests earlier-stage patients w/ intact immune systems for faster efficacy signals. Major Pathologic Response measurable in weeks vs years. Fondazione sponsors preserving runway to mid-2026. Dec ESMO-IO data + 2026 NEO-CYT results = multiple catalysts. Stock at $1.05 USD.
Read full article (1 min)